The serogroup C meningococcal conjugate vaccine is available since 1999. In the absence of randomized controlled trials that support a specific schedule, each country has adopted different vaccination programmes. Hereby, we analyse positive and negative aspects of the different vaccination strategies. CONCLUSION: While waiting for the introduction of other antimeningococcal vaccines, covering also for the Group B meningococci, further studies on effectiveness of an optimal schedule to be adopted in European countries are needed
Serogroup C Neisseria meningitidis invasive infection: Analysis of the possible vaccination strategies for a mass campaign / Chiappini E.; Venturini E.; Bonsignori F.; Galli L.; De Martino M.. - In: ACTA PAEDIATRICA. - ISSN 0803-5253. - ELETTRONICO. - 99:(2010), pp. 1609-1614. [10.1111/j.1651-2227.2010.01908.x]
Serogroup C Neisseria meningitidis invasive infection: Analysis of the possible vaccination strategies for a mass campaign
Chiappini E.;Venturini E.;Galli L.;
2010
Abstract
The serogroup C meningococcal conjugate vaccine is available since 1999. In the absence of randomized controlled trials that support a specific schedule, each country has adopted different vaccination programmes. Hereby, we analyse positive and negative aspects of the different vaccination strategies. CONCLUSION: While waiting for the introduction of other antimeningococcal vaccines, covering also for the Group B meningococci, further studies on effectiveness of an optimal schedule to be adopted in European countries are needed
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
